Management of Cardiovascular Disease in Kidney Disease (MaCK) Study

Summary

Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease (CKD). At present time the investigators do not have proven effective strategies to reduce high CVD related deaths in CKD. This study assesses a novel therapy (hydroxychloroquine, HCQ) for the treatment of CVD in patients with CKD. This is the first human proof-of-concept study and is planned to be conducted among US Veterans, who suffer from both CKD and CVD at a disproportionately greater rates. The outcome of this study has the potential to provide an entirely new line of therapy for the treatment of CVD in CKD.

Timeline

Start

2018-12-14

Primary completion

2024-01-31

Completion

2024-01-31

Publications

• Background Shukla AM, Segal MS, Pepine CJ, Cheung AK, Shuster J, Mohandas R, Martinez WM, Flint JJ, Shah SV. Management of Cardiovascular Disease in Kidney Disease Study: Rationale and Design. Am J Nephrol. 2021;52(1):36-44. doi: 10.1159/000513567. Epub 2021 Feb 26.
• Background Joyce M, Segal MS, Shukla AM. Ethics and Terminology for Opting In and Out. JAMA Intern Med. 2024 Apr 1;184(4):451-452. doi: 10.1001/jamainternmed.2023.7060. No abstract available.

Drugs

Indications